Heat stable hyaluronic acid compositions for dermatological use

Abstract

The disclosure provides hyaluronic acid (HA) gel formulations and methods for treating the appearance of the skin. The formulations contain hyaluronic acid and at least one additional ingredient. Methods for treating lines, wrinkles, fibroblast depletions, and scars with the disclosed composition are provided as well.

1 - 20 . (canceled) 
     
     
         21 . A method of improving the appearance of fine lines, wrinkles, fibroblast depletions, or scars of a patient, the method comprising administering a local injection of a steam sterilized dermal filler composition to the patient, wherein the appearance of the fine lines, wrinkles, fibroblast depletions, or scars is diminished by the injection, the dermal filler composition comprising crosslinked hyaluronic acid (HA), ascorbyl-2-glucoside and an anesthetic agent, wherein the dermal filler composition is steam-sterilization stable. 
     
     
         22 . The method of  claim 21 , wherein the hyaluronic acid is crosslinked with 1,4-butanediol diglycidyl ether. 
     
     
         23 . The method of  claim 21 , wherein the anesthetic agent is lidocaine. 
     
     
         24 . The method of  claim 23 , wherein the lidocaine is present in an amount of about 0.001% w/w to about 10% w/w. 
     
     
         25 . The method of  claim 23 , wherein the lidocaine is present in an amount of about 0.001% w/w to about 5% w/w. 
     
     
         26 . The method of  claim 23 , wherein the lidocaine is present in an amount of about 0.001% w/w to about 3% w/w. 
     
     
         27 . The method of  claim 23 , wherein the lidocaine is present in an amount of 0.3% w/w. 
     
     
         28 . The method of  claim 21 , wherein the crosslinked HA is present in an amount of about 1 mg/mL to about 40 mg/mL. 
     
     
         29 . The method of  claim 28 , wherein the crosslinked HA is present in an amount of about 10 mg/mL to about 40 mg/mL. 
     
     
         30 . The method of  claim 28 , wherein the crosslinked HA is present in an amount of about 20 mg/mL to about 30 mg/mL. 
     
     
         31 . The method of  claim 28 , wherein the crosslinked HA is present in an amount of about 20 mg/mL to about 25 mg/mL. 
     
     
         32 . The method of  claim 21 , wherein the ascorbyl-2-glucoside is present in an amount of about 0.001% w/w to about 10% w/w. 
     
     
         33 . The method of  claim 32 , wherein the ascorbyl-2-glucoside is present in an amount of about 0.1% w/w to about 3.0% w/w. 
     
     
         34 . The method of  claim 32 , wherein the ascorbyl-2-glucoside is present in an amount of 1% w/w. 
     
     
         35 . The method of  claim 32 , wherein the ascorbyl-2-glucoside is present in an amount of 2% w/w. 
     
     
         36 . The method of  claim 32 , wherein the ascorbyl-2-glucoside is present in an amount of 0.6% w/w. 
     
     
         37 . The method of  claim 21 , wherein the steam-sterilization stability of the dermal filler composition is determined by subjecting the dermal filler composition to a steam sterilization treatment at between about 120° C. and about 135° C. for between about 1 minute and about 5 minutes, with substantial retention after the treatment of one or more of the dermal filler characteristics of being clear, homogenous or cohesive. 
     
     
         38 . The method of  claim 37 , wherein the HA is crosslinked with 1,4-butanediol diglycidyl ether, and the anesthetic agent is lidocaine. 
     
     
         39 . The method of  claim 38 , wherein the crosslinked HA is present in an amount of about 10 mg/mL to about 40 mg/mL. 
     
     
         40 . The method of  claim 39 , wherein the ascorbyl-2-glucoside is present in an amount of about 0.1% w/w/to about 3.0% w/w, and the lidocaine is present in an amount of about 0.3% w/w to about 3% w/w.